A significant commitment of the CAMAC faculty is the translation of more fundamental science into diagnostic and therapeutic application. This work has included pre-clinical analyses for and clinical studies of the anti-BAFF monoclonal antibody (Chatham, Kimberly, Zhou) and of the anti-human death receptor 5 monoclonal antibody (Buchsbaum, Kimberly, Zhou).  Early work with induced pleuripotent stem cells in animal models of autoimmunity is showing substantial promise (Townes), while work with techniques in proteomics in RA is looking for markers of responsiveness to biologics (Barnes, Bridges, Grizzle, Mobley, Mountz).  Dr. Bridges also leads the Treatment Efficacy and Toxicity in RA Database and Respository (TETRAD; NIH RC2 AR 058964).  Dr. Henry Townsend is a new faculty junior member in the Division of Rheumatology with expertise in psoriatic arthritis and spondyloarthritis.  Further follow-up of biologics for the risk for infection among patients with autoimmune disease starting on biologics has led to more accurate assessment of clinical risk (Curits, Saag) in addition to funded projects focused on clinical trials of gout and osteoporosis as well as outcomes in rheumatic diseases.